DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Gamimune N (Immune Globulin) - Summary

 

-- advertisement --

GAMIMUNE N SUMMARY

Immune Globulin Intravenous (Human), 10% -- Gamimune® N, 10% treated with solvent/detergent is a sterile solution of human protein containing no preservative. Gamimune N, 10% consists of 9%-11% protein in 0.16-0.24 M glycine. Not less than 98% of the protein has the electrophoretic mobility of gamma globulin. Not less than 90% of the IgG is monomer. Also present are traces of IgA and of IgM. The distribution of IgG subclasses is similar to that found in normal serum. The measured buffer capacity is 35 mEq/L and the osmolality is 274 mOsmol/kg solvent.

Gamimune N, 10% is efficacious in the treatment of primary immunodeficiency states in which severe impairment of antibody forming capacity has been shown, such as: congenital agammaglobulinemias, common variable immunodeficiency, Wiskott-Aldrich syndrome, x-linked immunodeficiency with hyper IgM, and severe combined immunodeficiencies.5,21-23 Gamimune N, 10% is especially useful when high levels or rapid elevation of circulating antibodies are desired or when intramuscular injections are contraindicated.

In clinical situations in which a rapid rise in platelet count is needed to control bleeding or to allow a patient with ITP to undergo surgery, administration of Gamimune N, 10% should be considered.

GAMIMUNE N NEWS HIGHLIGHTS

Media Articles Related to Gamimune N (Immune Globulin)

respiratory syncytial virus immune globulin, human (RSV-IGIV)-inj, Respigam
Source: MedicineNet Respiratory Syncytial Virus Specialty [2005.03.02]

more>>

Published Studies Related to Gamimune N (Immune Globulin)

Effect of exercise on in vitro immune function: a 12-month randomized, controlled trial among postmenopausal women. [2008.06]

Effects of seven potential probiotic strains on specific immune responses in healthy adults: a double-blind, randomized, controlled trial. [2008.06]

Contribution of influenza immunity and virosomal-formulated synthetic peptide to cellular immune responses in a phase I subunit malaria vaccine trial. [2008.05]

Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. [2008.03.15]

Evaluation of the effects of human leukocyte IFN-alpha on the immune response to the HBV vaccine in healthy unvaccinated individuals. [2008.02.20]

more>>

Clinical Trials Related to Gamimune N (Immune Globulin)

Intravenous Immunoglobulin (IVIG) for Treatment of Unexplained Secondary Recurrent Miscarriage [Active, not recruiting]

more>>

Page last updated: 2008-08-10

-- advertisement -- The American Red Cross

We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2008